Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Zura Bio Limited - Class A Ordinary shares (ZURA)
Company Research
Source: Business Wire
Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseasesExpect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory BoardCash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its second quarter 2024 financial results, and recent business highlights."We have made meaningful prog
Show less
Read more
Impact Snapshot
Event Time:
ZURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZURA alerts
High impacting Zura Bio Limited - Class A Ordinary shares news events
Weekly update
A roundup of the hottest topics
ZURA
News
- Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock.MarketBeat
- Zura Bio Limited (NASDAQ: ZURA) is now covered by analysts at HC Wainwright. They set a "neutral" rating and a $5.00 price target on the stock.MarketBeat
- Zura Bio to Present at Three Upcoming Investor Conferences in SeptemberBusiness Wire
- Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding WarrantsBusiness Wire
ZURA
Sec Filings
- 9/18/24 - Form EFFECT
- 9/16/24 - Form S-3/A
- 9/13/24 - Form ARS
- ZURA's page on the SEC website